Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors

Immunotherapies in rare cancers

(2023) Sneha Vivekanandhan et al.   Molecular Cancer

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

(2023) Karama Makni Maalej et al.   Molecular Cancer

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models

(2023) Esther Schoutrop et al.   Journal for ImmunoTherapy of Cancer

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

(2022) Duygu Ozmadenci et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

(2022) Eugene Y Chiang et al.   Journal for ImmunoTherapy of Cancer

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer

(2022) Ingunn M Stromnes et al.   Journal for ImmunoTherapy of Cancer

MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer

(2022) Yike Li et al.   Frontiers in Oncology

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

(2022) Jiannan Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy

(2022) Wuyi Zeng et al.   Frontiers in Immunology

COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade

(2021) Kyle Hansen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mesothelin-specific CAR T cells target ovarian cancer

(2021) Esther Schoutrop et al.   CANCER RESEARCH

Next generation of immune checkpoint inhibitors and beyond

(2021) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy

(2021) Ping Yang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

(2021) William A. Freed-Pastor et al.   CANCER CELL

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway

(2021) Feng Ji et al.   Journal of Hematology & Oncology

Immune checkpoint inhibitors in melanoma

(2021) Matteo S Carlino et al.   LANCET

CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways

(2021) Lu Liu et al.   Frontiers in Oncology

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

(2021) J. Niu et al.   ANNALS OF ONCOLOGY

Engineering CAR-T Cells for Next-Generation Cancer Therapy

(2020) Mihe Hong et al.   CANCER CELL

TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro

(2020) Changkun Zhang et al.   JOURNAL OF IMMUNOTHERAPY

Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions

(2019) Stephen J. Bagley et al.   PHARMACOLOGY & THERAPEUTICS

Determinants of response and resistance to CAR T cell therapy

(2019) Stefanie Lesch et al.   SEMINARS IN CANCER BIOLOGY

Current challenges and emerging opportunities of CAR-T cell therapies

(2019) Teresa R. Abreu et al.   JOURNAL OF CONTROLLED RELEASE

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges

(2018) Zijun Zhao et al.   Acta Pharmaceutica Sinica B

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Mesothelin, a novel immunotherapy target for triple negative breast cancer

(2012) Julia Tchou et al.   BREAST CANCER RESEARCH AND TREATMENT

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

(2009) N. Stanietsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA